Kepenekian V, Bhatt A, Péron J, Alyami M, Benzerdjeb N, Bakrin N, Falandry C, Passot G, Rousset P, Glehen O (2022) Advances in the management of peritoneal malignancies. Nat Rev Clin Oncol 19(11):698–718. https://doi.org/10.1038/s41571-022-00675-5
Sugarbaker PH (1995) Peritonectomy procedures. Ann Surg 221(1):29–42. https://doi.org/10.1097/00000658-199501000-00004
Article CAS PubMed PubMed Central Google Scholar
González-Moreno S (2006) Peritoneal surface oncology: a progress report. Eur J Surg Oncol 32(6):593–596. https://doi.org/10.1016/j.ejso.2006.03.001
Sadeghi B, Arvieux C, Glehen O, Beaujard AC, Rivoire M, Baulieux J, Fontaumard E, Brachet A, Caillot JL, Faure JL, Porcheron J, Peix JL, François Y, Vignal J, Gilly FN (2000) Peritoneal carcinomatosis from non-gynecologic malignancies: results of the EVOCAPE 1 multicentric prospective study. Cancer 88(2):358–363. https://doi.org/10.1002/(sici)1097-0142(20000115)88:2%3c358::aid-cncr16%3e3.0.co;2-o
Article CAS PubMed Google Scholar
Cortés-Guiral D, Hübner M, Alyami M, Bhatt A, Ceelen W, Glehen O, Lordick F, Ramsay R, Sgarbura O, Van Der Speeten K, Turaga KK, Chand M (2021) Primary and metastatic peritoneal surface malignancies. Nat Rev Dis Primers 7(1):91. https://doi.org/10.1038/s41572-021-00326-6
Bhatt A, Mehta S, Seshadri RA. 2019 The current status of peritoneal surface oncology in India. Indian J Surg Oncol. (Suppl 1):41–48. https://doi.org/10.1007/s13193-018-00871-9
Bhatt A, Mehta S, Ramakrishnan As, Pande P, Rajan F, Rangole A, Saklani A, Sethna K, Singh S, Zaveri S, Gopinath KS. 2017 Setting up of the Indian HIPEC Registry: a registry for Indian patients with peritoneal surface malignancies. Indian J Surg Oncol. (4):527–532. https://doi.org/10.1007/s13193-017-0693-7
Bhatt A, Mehta SS, Zaveri S, Rajan F, Ray M, Sethna K, Katdare N, Patel MD, Kammar P, Prabhu R, Sinukumar S, Mishra S, Rangarajan B, Rangole A, Damodaran D, Penumadu P, Ganesh M, Peedicayil A, Raj H, Seshadri R (2018) Treading the beaten path with old and new obstacles: a report from the Indian HIPEC registry. Int J Hyperthermia 35(1):361–369. https://doi.org/10.1080/02656736.2018.1503345
Moran BJ, Tzivanakis A (2018) The concept of “obstruction-free survival” as an outcome measure in advanced colorectal cancer management. Pleura Peritoneum 3(1):20180101. https://doi.org/10.1515/pp-2018-0101
Article PubMed PubMed Central Google Scholar
Goéré D, Malka D, Tzanis D, Gava V, Boige V, Eveno C, Maggiori L, Dumont F, Ducreux M, Elias D (2013) Is there a possibility of a cure in patients with colorectal peritoneal carcinomatosis amenable to complete cytoreductive surgery and intraperitoneal chemotherapy? Ann Surg 257(6):1065–1071. https://doi.org/10.1097/SLA.0b013e31827e9289
Chia CS, You B, Decullier E, Vaudoyer D, Lorimier G, Abboud K, Bereder JM, Arvieux C, Boschetti G, Glehen O (2016) BIG RENAPE Group. Patients with peritoneal carcinomatosis from gastric cancer treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: is cure a possibility? Ann Surg Oncol. 23(6):1971–1979. https://doi.org/10.1245/s10434-015-5081-3
Article CAS PubMed Google Scholar
Chua TC, Moran BJ, Sugarbaker PH, Levine EA, Glehen O, Gilly FN, Baratti D, Deraco M, Elias D, Sardi A, Liauw W, Yan TD, Barrios P, Gómez Portilla A, de Hingh IH, Ceelen WP, Pelz JO, Piso P, González-Moreno S, Van Der Speeten K, Morris DL (2012) Early- and long-term outcome data of patients with pseudomyxoma peritonei from appendiceal origin treated by a strategy of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. J Clin Oncol 30(20):2449–2456. https://doi.org/10.1200/JCO.2011.39.7166
Jacquet P, Sugarbaker PH (1996) Clinical research methodologies in diagnosis and staging of patients with peritoneal carcinomatosis. In: Sugarbaker PH (ed) Peritoneal carcinomatosis: principles of management. Kluwer Academic publishers, Boston, pp 359–374
Common terminology criteria for adverse events (CTCAE) https://www.eortc.be › services › doc › ctc › ctcae_4.... Accessed 20th December, 2022
Sinukumar S, Mehta S, As R, Damodaran D, Ray M, Zaveri S, Kammar P, Bhatt A (2019) Analysis of clinical outcomes of pseudomyxoma peritonei from appendicular origin following cytoreductive surgery and hyperthermic intraperitoneal chemotherapy-a retrospective study from INDEPSO. Indian J Surg Oncol. 10(Suppl 1):65–70. https://doi.org/10.1007/s13193-018-00870-w
Article PubMed PubMed Central Google Scholar
Bhatt A, Kammar P, Mehta S, Damodaran D, Zaveri S, Patel MD, Sinukumar S, Ray M, Seshadri R. 2019 Chasing rainbows? The possibility of “cure” in patients with colorectal peritoneal metastases undergoing cytoreductive surgery and HIPEC-a retrospective study by INDEPSO.Indian J Surg Oncol. (Suppl 1):49–56. https://doi.org/10.1007/s13193-019-00879-9
Piñeros M, Abriata MG, de Vries E, Barrios E, Bravo LE, Cueva P, de Camargo CM, Fernández L, Gil E, Luciani S, Pardo C, Zoss W, Bray F, Mery L (2021) Progress, challenges and ways forward supporting cancer surveillance in Latin America. Int J Cancer 149(1):12–20. https://doi.org/10.1002/ijc.33407
Article CAS PubMed Google Scholar
Pinheiro PS, Morris CR, Liu L, Bungum TJ, Altekruse SF (2014) The impact of follow-up type and missed deaths on population-based cancer survival studies for Hispanics and Asians. J Natl Cancer Inst Monogr 2014(49):210–217. https://doi.org/10.1093/jncimonographs/lgu016
Article PubMed PubMed Central Google Scholar
Kusamura S, Barretta F, Yonemura Y, Sugarbaker PH, Moran BJ, Levine EA, Goere D, Baratti D, Nizri E, Morris DL, Glehen O, Sardi A, Barrios P, Quénet F, Villeneuve L, Gómez-Portilla A, de Hingh I, Ceelen W, Pelz JOW, Piso P, González-Moreno S, Van Der Speeten K, Deraco M (2021) Peritoneal Surface Oncology Group International (PSOGI) and the French National Registry of Rare Peritoneal Surface Malignancies (RENAPE) The role of hyperthermic intraperitoneal chemotherapy in pseudomyxoma peritonei after cytoreductive surgery. JAMA Surg 156(3):e206363. https://doi.org/10.1001/jamasurg.2020.6363
Article PubMed PubMed Central Google Scholar
Habinshuti P, Hagenimana M, Nguyen C, Park PH, Mpunga T, Shulman LN, Fehr A, Rukundo G, Bigirimana JB, Teeple S, Kigonya C, Ndayisaba GF, Uwinkindi F, Randall T, Miller AC (2020) Factors associated with loss to follow-up among cervical cancer patients in Rwanda. Ann Glob Health 86(1):117. https://doi.org/10.5334/aogh.2722
Article PubMed PubMed Central Google Scholar
Alyami M, Kim BJ, Villeneuve L, Vaudoyer D, Képénékian V, Bakrin N, Gilly FN, Cotte E, Glehen O, Passot G (2018) Ninety-day post-operative morbidity and mortality using the National Cancer Institute’s common terminology criteria for adverse events better describe post-operative outcome after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. Int J Hyperthermia 34(5):532–537. https://doi.org/10.1080/02656736.2017.1367846
Rau B, Brandl A, Piso P et al (2020) Peritoneal metastasis in gastric cancer: results from the German database. Gastric Cancer 23:11–22. https://doi.org/10.1007/s10120-019-00978-0
Baratti D, Kusamura S, Cabras AD, Bertulli R, Hutanu I, Deraco M (2013) Diffuse malignant peritoneal mesothelioma: long-term survival with complete cytoreductive surgery followed by hyperthermic intraperitoneal chemotherapy (HIPEC). Eur J Cancer 49(15):3140–3148. https://doi.org/10.1016/j.ejca.2013.05.027
Kusamura S, Torres Mesa PA, Cabras A, Baratti D, Deraco M (2016) The role of Ki-67 and pre-cytoreduction parameters in selecting diffuse malignant peritoneal mesothelioma (DMPM) patients for cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC). Ann Surg Oncol 23(5):1468–1473. https://doi.org/10.1245/s10434-015-4962-9
Cazauran JB, Lasseur A, Pasquer A et al (2017) Total mesenteric peritonectomy for peritoneal metastases (with video). Ann Surg Oncol. https://doi.org/10.1245/s10434-017-6099-5
Bristow RE, Tomacruz RS, Armstrong DK, Trimble EL, Montz FJ (2002) Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis. J Clin Oncol 20(5):1248–1259. https://doi.org/10.1200/JCO.2002.20.5.1248
Eisenhauer EL, Abu-Rustum NR, Sonoda Y, Levine DA, Poynor EA, Aghajanian C, Jarnagin WR, DeMatteo RP, D’Angelica MI, Barakat RR, Chi DS (2006) The addition of extensive upper abdominal surgery to achieve optimal cytoreduction improves survival in patients with stages IIIC-IV epithelial ovarian cancer. Gynecol Oncol 103(3):1083–1090. https://doi.org/10.1016/j.ygyno.2006.06.028
Fagotti A, Ferrandina MG, Vizzielli G, Pasciuto T, Fanfani F, Gallotta V, Margariti PA, Chiantera V, Costantini B, GueliAlletti S, Cosentino F, Scambia G (2020) Randomized trial of primary debulking surgery versus neoadjuvant chemotherapy for advanced epithelial ovarian cancer (SCORPION-NCT01461850). Int J Gynecol Cancer 30(11):1657–1664. https://doi.org/10.1136/ijgc-2020-001640
Harter P, Sehouli J, Vergote I, Ferron G, Reuss A, Meier W, Greggi S, Mosgaard BJ, Selle F, Guyon F, Pomel C, Lécuru F, Zang R, Avall-Lundqvist E, Kim JW, Ponce J, Raspagliesi F, Kristensen G, Classe JM, Hillemanns P, Jensen P, Hasenburg A, Ghaem-Maghami S, Mirza MR, Lund B, Reinthaller A, Santaballa A, Olaitan A, Hilpert F, du Bois A (2021) DESKTOP III Investigators. Randomized trial of cytoreductive surgery for relapsed ovarian cancer. N Engl J Med 385(23):2123–2131. https://doi.org/10.1056/NEJMoa2103294. Erratum.In:NEnglJMed.386(7):704
留言 (0)